Effects of a new advanced glycation inhibitor, LR-90, on mitigating arterial stiffening and improving arterial elasticity and compliance in a diabetic rat model: aortic impedance analysis

Br J Pharmacol. 2014 Jun;171(12):3103-14. doi: 10.1111/bph.12656.

Abstract

Background and purpose: We determined the effects of treatment with LR-90, an inhibitor of advanced glycation end products, on the mechanical properties of the arterial system in streptozotocin (STZ)-induced diabetic Sprague Dawley rats, using aortic impedance analysis, and further investigated the effects of LR-90 on the progression of aortic pathology.

Experimental approach: STZ-induced diabetic rats were treated with or without LR-90 (50 mg L(-1) in drinking water) for 8 weeks and compared with control groups. Arterial BP measurements, various metabolic parameters, aortic histopathology, collagen cross-linking, AGE accumulation, and RAGE protein expression in aortic tissue were determined. Pulsatile parameters were evaluated using a standard Fourier series expansion technique and impulse response function of the filtered aortic input impedance spectra.

Key results: LR-90 reduced glycated haemoglobin and triglycerides levels, although it had no effect on the glycaemic status. LR-90 did not affect arterial BP, but prevented the diabetes-induced increase in peripheral resistance and variations in aortic distensibility, as it reduced aortic characteristic impedance by 21%. LR-90 also prevented the elevation in wave reflection factor, as indicated by a 22.5% reduction and an associated increase of 23.5% in wave transit time, suggesting it prevents the augmentation of the systolic load of the left ventricle. Moreover, LR-90 inhibited collagen cross-linking and the accumulation of AGE and RAGE in the vasculature of diabetic rats.

Conclusions and implications: Treatment with LR-90 may impart significant protection against diabetes-induced aortic stiffening and cardiac hypertrophy and provides an additional therapeutic option for treatment of AGE associated diabetic complications.

Keywords: Advanced glycation end products; LR-90; aortic characteristic impedance; aortic distensibility; wave reflection factor; wave transit time.

MeSH terms

  • Animals
  • Aorta / drug effects*
  • Aorta / metabolism
  • Aorta / pathology
  • Aorta / physiopathology
  • Blood Pressure / drug effects
  • Butyrates / pharmacology*
  • Cardiomegaly / blood
  • Cardiomegaly / physiopathology
  • Cardiomegaly / prevention & control
  • Collagen / metabolism
  • Compliance
  • Diabetes Mellitus, Experimental / blood
  • Diabetes Mellitus, Experimental / drug therapy*
  • Diabetes Mellitus, Experimental / pathology
  • Diabetes Mellitus, Experimental / physiopathology
  • Diabetic Angiopathies / blood
  • Diabetic Angiopathies / pathology
  • Diabetic Angiopathies / physiopathology
  • Diabetic Angiopathies / prevention & control*
  • Glycated Hemoglobin / metabolism
  • Glycation End Products, Advanced / antagonists & inhibitors*
  • Glycation End Products, Advanced / metabolism
  • Hypoglycemic Agents / pharmacology*
  • Male
  • Rats, Sprague-Dawley
  • Receptor for Advanced Glycation End Products
  • Receptors, Immunologic / drug effects
  • Receptors, Immunologic / metabolism
  • Time Factors
  • Triglycerides / blood
  • Vascular Resistance / drug effects
  • Vascular Stiffness / drug effects*

Substances

  • Butyrates
  • Glycated Hemoglobin A
  • Glycation End Products, Advanced
  • Hypoglycemic Agents
  • LR-90
  • Receptor for Advanced Glycation End Products
  • Receptors, Immunologic
  • Triglycerides
  • Collagen